Impact Biomedical (IBO) Asset Utilization Ratio (2025 - 2026)

Impact Biomedical (IBO) posted Asset Utilization Ratio of 0.0 for Q1 2026, up 38.31% on a QoQ basis from 0.0 in Q3 2025.

Impact Biomedical (IBO) Asset Utilization Ratio (2025 - 2026) Analysis & Trends

Impact Biomedical's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Impact Biomedical	47.44 Mn	50.67 Mn	-	0.00

Download Data